leisure time -WSS

leisure time

author：explore 2025-09-30 18:42:56 - browse：6

Eric Lander White House science office — Eric Lander resigned as President Biden’s science adviser, after a White House investigation found “credible evidence” that he had violated workplace conduct rules. Photo illustration: Alex Hogan/STAT; Source: Getty

WASHINGTON — An early sign that trouble was afoot in the White House science office came last November, when roughly a dozen of Eric Lander’s staff formed a “culture committee” aimed at improving morale.

The group’s first action, five aides told STAT, was to create a “word cloud” depicting the adjectives they most often used to describe the work environment at the White House Office of Science and Technology Policy. Of the dozens of words submitted, three in particular stood out: “hostile,” “siloed,” and “aggressive.”

Three months later, Lander resigned as President Biden’s science adviser, after Politico reported a White House investigation that found “credible evidence” that he had violated workplace conduct rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Telehealth for opioid use disorder is lifesaving

entertainment

WSS

White House touts steps to stem shortages of cancer treatments

IRA could hurt research into orphan drugs for rare diseases

PEPFAR is under serious threat — and so is global health

Ozempic has benefits for kidney disease as well as diabetes

First over

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

focus

leisure time

hotspot

Supreme Court strikes down use of affirmative action

FDA proposes changes to key medical devices approval pathway

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biden's 'march

Trump demands the U.S. pay no more for drugs than other countries … again

FDA panel endorses Alnylam’s heart drug — after picking it apart

Medical leaders decry Supreme Court decision on affirmative action

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Trump demands the U.S. pay no more for drugs than other countries … again

The untold story of TV’s first prescription drug ad

knowledge

FDA panel endorses Alnylam’s heart drug — after picking it apart

Medicare drug price negotiation hearing pits pharma v Biden admin

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

IRA could hurt research into orphan drugs for rare diseases

Regeneron agrees to White House price limits on anti

Popular nasal decongestant doesn't actually relieve congestion

focus

entertainment

entertainment

entertainment